Zak Mir talks to Tim McCarthy, CEO ImmuPharma, in the wake of a series of announcements this year which have transformed the outlook for the AIM listed (LSE:IMM) evolving speciality pharma company.
17 March 2025
Tim McCarthy, CEO of ImmuPharma talks to Zak MIr at ‘Traders Cafe’ focusing on the UK biotech arena as a public company together with two key significant scientific announcements issued by ImmuPharma over the last period, including more details on the MOA of IMMs auto-immune technology platform, P140 – March 2025